» Articles » PMID: 16416732

Mesothelin is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic Pancreatitis

Overview
Specialty Pathology
Date 2006 Jan 19
PMID 16416732
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Mesothelin, a cell surface glycoprotein present on normal mesothelial cells, has been reported to be expressed in pancreatic adenocarcinomas. We conducted this study to fully characterize mesothelin expression in surgically resected, formalin-fixed, paraffin-embedded tissue specimens of 18 pancreatic adenocarcinomas, 9 adenocarcinomas of the ampulla of Vater, 12 adenocarcinomas of the common bile duct, and 17 cases of chronic pancreatitis. Mesothelin immunostaining was performed using the antimesothelin monoclonal antibody 5B2. All 18 cases (100%) of pancreatic adenocarcinomas showed mesothelin expression, as did 8 (89%) of 9 cases of ampullar adenocarcinoma and all 12 cases (100%) of common bile duct adenocarcinoma. In all cases of pancreaticobiliary adenocarcinoma, the adjacent normal pancreas did not stain for mesothelin. Of 17 specimens of chronic pancreatitis, 16 were negative for mesothelin expression, and 1 case showed weak mesothelin staining of fewer than 5% of normal pancreatic ducts. Our results demonstrated mesothelin expression in the majority of pancreaticobiliary adenocarcinomas and no expression in normal pancreatic tissues and in chronic pancreatitis.

Citing Articles

Rehabilitation for Functioning and Quality of Life in Patients with Malignant Pleural Mesothelioma: A Scoping Review.

Lippi L, de Sire A, Aprile V, Calafiore D, Folli A, Refati F Curr Oncol. 2024; 31(8):4318-4337.

PMID: 39195305 PMC: 11352897. DOI: 10.3390/curroncol31080322.


Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.

Chen Q, Sun Y, Li H Discov Oncol. 2024; 15(1):289.

PMID: 39023820 PMC: 11258118. DOI: 10.1007/s12672-024-01159-x.


Biology of Mesothelin and Clinical Implications: A Review of Existing Literature.

Hagerty B, Takabe K World J Oncol. 2023; 14(5):340-349.

PMID: 37869242 PMC: 10588497. DOI: 10.14740/wjon1655.


: a promising vector for tumor immunotherapy.

Ding Y, Shu L, He R, Chen K, Deng Y, Zhou Z Front Immunol. 2023; 14:1278011.

PMID: 37868979 PMC: 10587691. DOI: 10.3389/fimmu.2023.1278011.


Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.

Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L J Cancer Res Clin Oncol. 2023; 149(16):15027-15038.

PMID: 37612388 DOI: 10.1007/s00432-023-05279-9.